Drug Trial Radar · NCT04008186
A Clinical Drug-Drug Interaction (DDI) Study With Omaveloxolone
Last checked: Nov 19, 2026Latest source record: May 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
61
Actual
Start
Jun 14, 2019
Primary completion
Aug 18, 2019
Study completion Aug 28, 2019
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- Collaborators
- Covance
- First posted
- Jul 5, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will assess the potential for clinical drug-drug interactions between omaveloxolone and a number of substrates and inhibitors of metabolic enzymes and drug transporters.
Conditions
- Healthy Adult Subjects
Interventions
OmaveloxoloneDrug
50 mg capsules
Midazolam oral solutionDrug
2 mg/mL oral solution
Repaglinide 1 MGDrug
1 mg tablet
MetFORMIN 500 Mg Oral TabletDrug
500 mg tablet
RosuvastatinDrug
10 mg tablet
Digoxin tabletDrug
0.25 mg tablet
Gemfibrozil TabletsDrug
600 mg tablet
Itraconazole capsuleDrug
100 mg capsule
Verapamil PillDrug
120 mg tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 - Maximum concentration (Cmax) of probe drugs co-administered with omaveloxolone (midazolam, repaglinide, metformin, rosuvastatin, and digoxin)Time frame: 28 days
- Part 1 - Area under the plasma concentration-time curve of (AUC) for probe drugs co-administered with omaveloxolone (midazolam, repaglinide, metformin, rosuvastatin, and digoxin)Time frame: 28 days
- Part 2 - Maximum concentration (Cmax) of omaveloxoloneTime frame: 23 days
- Part 2 - Area under the omaveloxolone concentration-time curve (AUC)Time frame: 23 days
- Part 3 - Maximum concentration (Cmax) of omaveloxoloneTime frame: 23 days
- Part 3 - Area under the omaveloxolone concentration-time curve (AUC)Time frame: 28 days
- Part 4 - Maximum concentration (Cmax) of omaveloxoloneTime frame: 23 days
- Part 4 - Area under the omaveloxolone concentration-time curve (AUC)Time frame: 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Covance Clinical Research Unit (CRU) Inc.
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.